MEDICAL PIPELINE
XANA™ is currently carrying out two clinical trials with the goal to obtain in the future both CE & FDA Certification using auricular vagus nerve stimulation.
PRIMARY INSOMNIA
Chronic insomnia is highly prevalent and affects over 30% of the general population.
Insomnia impairs cognitive and physical functioning and is associated with a wide range of impaired daytime functions across several emotional, social, and physical domains.
Currently, we are conducting a clinical Proof of Concept (POC) and will be starting a multicentric pivotal clinical trial in 2024.
This research is beaing coordinated by Dr. Iñaki Gurtubay, Head of the Sleep Unit at, the University Hospital of Navarra, Spain.
HEART FAILURE
Heart failure with preserved ejection fraction (HFPEF) is a common condition, especially among the elderly and women, with the reported prevalence approaching 10% in women over the age of 80 years.
With an increasing prevalence of hypertension, obesity, atrial fibrillation, and diabetes, and the growing elderly segment of the general population, the prevalence of HFPEF is projected to increase further. Heart failure with preserved ejection fraction (HFpEF)
We are conducting a 1 year clinical trial in a Hospital in Spain under Dr. David Calvo, Senior Cardiologist at the University Hospital San Carlos of Madrid) in collaboration with the University Hospital of Aviles, Spain.
SWITZERLAND
Xana Stim Sárl
Switzerland Innovation Park
Basel Area AG Jura Site
Place des Sciences 2
2822 Correaux, Switzerland
+41 21 588 04 55
SPAIN
Xana Innovation SL
C/Los Prados 166
33203, Gijón, Asturias
+34 984 300 141